Navigation Links
Bortezomib in Medical News

ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity

ATLANTA, GA, December 8, 2007 -- Results from two investigational Phase I trials of ZOLINZA (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma. Data from one study showed that 10 of 21 (48 percent) evalu...

Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma

... multiple myeloma patients previously treated with bortezomib (VELCADE((R))). The SPA provides agreement that t...d Safety of Perifosine Added to the Combination of bortezomib and Dexamethasone in Multiple Myeloma Patients Pre... safety of KRX-0401 vs. placebo when combined with bortezomib and dexamethasone. The trial, powered at 90%, wil...

Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop

... Phase I study of elotuzumab (HuLuc63) in combination with bortezomib in relapsed multiple myeloma Lead investigator: Andrzej Jakubo...30 pm ET Panobinostat & bortezomib phase I trial in multiple myeloma Lead investigator: Orhan Se...

Green tea may negate the effects of a common cancer therapy

...ract the anticancer effects of one cancer therapy, bortezomib (Velcade ), and may be contraindicated for pati...valuated whether the combination of green tea and bortezomib would improve outcomes against multiple myeloma, ...d to find that the EGCG compound seemed to prevent bortezomib from fighting the disease by blocking its proteas...

Green Tea May Negate the Effects of a Common Cancer Therapy

...ract the anticancer effects of one cancer therapy, bortezomib (Velcade(R)), and may be contraindicated for patie...evaluated whether the combination of green tea and bortezomib would improve outcomes against multiple myeloma, a...d to find that the EGCG compound seemed to prevent bortezomib from fighting the disease by blocking its proteaso...

Cancer drug effectively treats transplant rejections

...ge role in the humoral immune response by making immune proteins that attack transplanted organs. "We found a body of literature demonstrating that bortezomib works well in suppressing transplant rejection in the laboratory," says Woodle, lead author of the study and chief of transplant surgery at UC. "Moreo...

Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology

...2 Clinical Trial of Perifosine in combination with bortezomib (+/- dexamethasone) on Tuesday, December 9, 2008 a... of a Multicenter Trial of Perifosine (KRX-0401) + bortezomib in Patients with Relapsed or Relapsed / Refractory...btained to date on the combination of KRX-0401 and bortezomib in relapsed and refractory multiple myeloma patien...

VCU Massey Cancer Center spearheads novel clinical study for lymphoma patients

...interactions between proteasome inhibitors such as bortezomib and histone deacetylase inhibitors such as vorinos...sess whether patients who have previously received bortezomib respond differently from those who have never been treated with bortezomib. bortezomib administered alone has recently been approved for ...

Combination Therapy Helps to Combat Myeloma

...at preclude them from receiving high doses of the standard drug therapies melphalan and prednisone, or a transplant, experts said. "The addition of bortezomib (Velcade) resulted in significant prolongation in time to disease progression with a reduction of 52 percent in risk of progression," said lead resear...

FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma

...A(1) trial showed 30% complete remission rate with bortezomib compared to 4% for the control arm. Importantly, patients treated with bortezomib also experienced a survival benefit," said Paul Ri...ur days every 6 weeks or the same MP schedule with bortezomib (1.3 mg/m2) IV on days 1, 4, 8, 11, 22, 25, 29 and...
Bortezomib in Medical Technology

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced updated clinical results from an ongoing Phase 1/2...

Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma

- First of three ongoing randomized chemotherapy combination trials to evaluate HGS-ETR1 in the treatment of specific cancers - ROCKVILLE, Md., Sept. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today reported initial topline results from an ongoing randomiz...

Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome

...57 induces an anti-inflammatory response at doses less than one tenth the Maximum Tolerated Dose (MTD). In contrast, nonselective inhibitors, such as bortezomib and carfilzomib, induce anti-inflammatory responses only at or near their MTD. These findings also underline the key role played by the immunoproteas...

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

...tients enrolled in the Phase 2 trial have relapsed following treatment with bortezomib and an immunomodulatory agent, such as thalidomide or lenalidomide, and wer...ase 2 clinical trial designed to evaluate response rates based on patients' bortezomib treatment history demonstrated substantial response rates, particularly amo...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... Phase 1/2 study of perifosine in combination with bortezomib (+/- dexamethasone) in multiple myeloma patients relapsed from or refractory to bortezomib NEW YORK, Dec. 9 /PRNewswire-FirstCall/ -...ivity of perifosine (KRX-0401) in combination with bortezomib (+/- dexamethasone) in patients with relapsed/refr...

New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia

...cer Centers-Parker: Results of a Phase II study of bortezomib in patients with relapsed or refractory indolent l...ncer Centers-Midtown: Phase II open label-trial of bortezomib in patients with multiple myeloma who have undergo... Centers-Midtown: Phase II trial of combination of bortezomib and Rituximab in relapsed and/or refractory Walden...

Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology

...6:00 p.m. -- 8:00 p.m. PST Session: Molecular Pharmacology, Drug Resistance Poster II -- Non-Proteasomal Targets of Proteasome Inhibitors bortezomib and Carfilzomib (Abstract #2657) Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding Therapy Poster II ...

Telik's Proteasome Inhibitor Program Meets a Preclinical Development Milestone

.... Telik's proteasome inhibitors are orally active, non-peptide, non-boron based, and thus may lead to a drug candidate that might have advantages over bortezomib and other proteasome inhibitors. "The potentially favorable profile of these compounds was achieved through the use of our TRAP(R) computational dru...

Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma

...to evaluate patients' overall response rate after four cycles of carfilzomib. All patients enrolled in the trial have received prior treatment(s) with bortezomib and either lenalidomide or thalidomide and are refractory to their last treatment. A second open-label, multi-center Phase 2 trial of single-agent c...

Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...and helping patients fight cancer." Data from the following studies will be presented: -- The Effect of Pegylated Liposomal Doxorubicin Plus bortezomib in Multiple Myeloma Patients with Renal Insufficiency (Abstract 8562) Presentation: Saturday, May 31, 8:00 am - 12:00 pm CST, General ...

More>>

Bortezomib in Biological News

Massey researchers induce cell death in leukemia

...or of translational research, interactions between bortezomib and romidepsin (Gloucester Pharmaceuticals) and bortezomib with belinostat (aka PXD101 from CuraGen Corporati...ed in human CLL cells isolated from five patients. bortezomib dramatically potentiated the lethality of both age...

An AIDS-related virus tricks cells to become tumors, new Penn study finds

...n be free to activate genes involved in growth of blood vessels to increase the blood supply to the tumor. "Use of such proteosome inhibitors as bortezomib as cancer therapeutic agents has been ongoing for the last four to five years and this study provides crucial step in understanding the mechanism for ...

Compound from marine bacteria shows potential as multiple myeloma therapy

...teasome inhibition is a key therapeutic target and bortezomib (Velcade tm) was the first in a new class of comp... Though less toxic than conventional chemotherapy, bortezomib does have significant side effects in some myeloma...e resistant to bortezomib. Because NPI-0052 and bortezomib attack the same intracellular target in different ...
Bortezomib in Biological Technology

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

... multiple myeloma patients previously treated with bortezomib (VELCADE(R)). The SPA provides agreement that the ...d Safety of Perifosine Added to the Combination of bortezomib and Dexamethasone in Multiple Myeloma Patients Pre...afety of perifosine vs. placebo when combined with bortezomib and dexamethasone. The trial, powered at 90%, will...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

...l cancer and in combination with capecitabine for advanced metastatic colon cancer (placebo-controlled), as well as for perifosine in combination with bortezomib +/- dexamethasone in relapsed and refractory myeloma. About AEterna Zentaris Inc. AEterna Zentaris Inc. is a global biopharmaceutical compan...

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

...al trial to date, of which 45 percent had no prior bortezomib experience and 55 percent relapsed following bortezomib treatment. In both arms, substantial response rat...s not been reached. Among patients with prior bortezomib exposure, 18 percent achieved partial responses an...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...tation and posters: Relationship of rapid M protein reduction to outcomes in a trial of pegylated liposomal doxorubicin (PLD) plus bortezomib (B) versus B alone in previously treated multiple myeloma (MM) (Abstract 8591) General Poster Session, Saturday May 30, 8:00 am to 12:00 pm, Level...

Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting

...trial is an open-label multi-center study of single-agent carfilzomib in patients who have previously failed at least two prior treatments, containing bortezomib and either lenalidomide or thalidomide, and are refractory to their last treatment. In addition, results from a Phase Ib/II study of carfilzomib in p...

Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology

...Activity in Relapsed Patients by Prior Exposure to bortezomib A second presentation by Dr. Vij described...gned to evaluate response rates based on patients' bortezomib treatment history. Patients enrolled in this tria...: Non-Proteasomal Targets of Proteasome Inhibitors bortezomib and Carfilzomib (Abstract #2657) and The Selective...

Cystic Fibrosis - Axentis Pharma Takes Over Patents and Continues Development of Innovative Platform Technology

...lecules for the enzymatic removal of ubiquitin markers in incorrectly folded proteins. The inventions also protect the use of the proteasome inhibitor bortezomib (Velcade (R)) for second medical use in cystic fibrosis (Velcade (R) has already been approved for use in humans to treat other indications). For ...

Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference

...echanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breas...

Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference

...echanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breas...

Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook

...echanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breas...
Bortezomib in Biological Dictionary

Proteasome

...easome , COP9 signalosome and related complexes) ... Proteasome , COP9 signalosome, TPPII ... Proteasome inhibitor drug for treating cancer. ... bortezomib is a highly selective, reversible inhibitor of the 26S proteasome . ... The Proteasome -Glo™ Cell-Based Assays(a,b) are homogeneous, luminescent ...
Other Tags
(Date:7/11/2014)... 2014 The report, “Specialty Synthetic ... & Geography - 2018,” defines and segments the ... an analysis and forecast of the volumes and ... (Para aramids, meta aramids, UHMW Polyethylene, carbon fiber, ... fiber, PBI fiber, PBO fiber, and liquid crystal ...
(Date:7/11/2014)... July 11, 2014 Utilizing the Keller ... Dr. William Koenig, has topped a record number of ... has performed over 400 successful procedures without the occurrence ... is well known across the country for his expertise ... record has long been the foundation for numerous studies ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... 11, 2014 The report “Probiotics ... Nutrients, Animal Feed), Applications (Regular, Therapeutic, Preventive Health ... Trends & Forecasts to 2019 ” defines and ... and forecasting of the market value of probiotic ... driving and restraining factors for the global market ...
(Date:7/11/2014)... Global enterprises today are shifting towards the ... activities. Managed services offer these global enterprises a strategic ... resulted into rising operational costs to companies. The aim ... be the global market driver for expanding the managed ... services market is estimated to grow from $142.75 billion ...
Breaking Medicine News(10 mins):Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4
(Date:7/11/2014)... for Bone and Mineral Research awarded Michael F. Holick, ... with the 2014 Louis V. Avioli Award. Holick, a ... internationally known for revolutionizing the understanding of vitamin D ... award honors a member of the American Society for ... bone and mineral basic research. It is named for ...
(Date:7/11/2014)... the National Institute of Standards and Technology (NIST) ... more effectively, they often prove that necessity is ... case recently for M. Lorna De Leoz and ... specialization of glycomics. Glycomics is the study of ... are attached to proteins and lipids and influence ...
(Date:7/11/2014)... international team of researchers, including scientists from the Max ... a reported a major step in understanding photosynthesis, the ... maintains the oxygen in its atmosphere and which is ... earth. , The researchers report the first direct ... namely the step in which a specific protein complex, ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2A first direct glimpse of photosynthesis in action 2
Other Contents